Ipamorelin Research Index
Ipamorelin is a third-generation synthetic pentapeptide growth hormone releasing peptide (GHRP) that selectively activates GHS-R1a — the ghrelin receptor — on anterior pituitary somatotrophs. Unlike first- and second-generation GHRPs such as GHRP-6 and GHRP-2, Ipamorelin is specifically studied for its high hormonal selectivity: it stimulates GH release with minimal co-stimulation of cortisol, ACTH, or prolactin. This selectivity profile makes Ipamorelin the preferred GHRP for laboratory research requiring isolated GH axis activation. Ipamorelin has a half-life of approximately 2 hours in research models, producing episodic GH pulses via the Gq/11 → PLCβ → IP3/DAG → calcium/PKC intracellular signaling cascade. It is frequently studied in combination with GHRH analogs such as CJC-1295 and Sermorelin to activate complementary GH axis receptor systems for dual-pathway GH amplification research. All content on this page is for investigational and laboratory research purposes only.
17 research pages — for investigational use only
Ipamorelin vs GHRP-6
Selective GHS-R1a agonist vs first-generation benchmark GHRP — cortisol co-stimulation, selectivity, and GH pulse profile compared.
Ipamorelin vs Sermorelin
GHS-R1a ghrelin receptor GHRP vs GHRH receptor analog — complementary pathways for dual GH axis research.
CJC-1295 vs Ipamorelin
The most studied dual-pathway GH protocol: GHRH receptor (cAMP/PKA) vs ghrelin receptor (calcium/PKC) — synergistic.
Ipamorelin vs Tesamorelin
Cross-class GH axis comparison: selective ghrelin receptor GHRP vs full-length GHRH analog.
Ipamorelin vs GHRP-2
Selectivity-optimized 3rd-gen GHRP vs high-potency 2nd-gen benchmark — clean GH pulse vs maximum GHS-R1a agonism.
Ipamorelin Mechanism of Action
Step-by-step GHS-R1a receptor binding, pituitary GH pulse induction, and why Ipamorelin is the cleanest GH secretagogue studied in laboratory settings.
Ipamorelin vs GHRP-6 Side Effects
Side effect profile comparison: cortisol, appetite, prolactin, and water retention across both GHRPs.
Ipamorelin vs GHRP-6 Results Timeline
Phase-by-phase research timeline from acute GH pulse to IGF-1 changes to body composition endpoints.
Ipamorelin vs GHRP-6 for Fat Loss
GH-driven lipolysis research: which GHRP produces a cleaner fat loss signal without appetite confounds?
Ipamorelin vs GHRP-6 for Muscle Growth
GH/IGF-1/mTOR anabolic pathway comparison — cortisol co-stimulation as the key differentiator for muscle research.
Sermorelin vs Ipamorelin for GH Optimization
GH synthesis via GHRHR vs GH release via GHS-R1a — combined use produces supra-additive GH pulses in dual-receptor models.
Sermorelin vs Ipamorelin Differences
Five key differences: receptor class, synthesis vs release, half-life kinetics, GH pulse characteristics, and somatostatin sensitivity.
Sermorelin vs Ipamorelin Results
Research outcomes: GH pulse size, IGF-1 elevation, and body composition changes — combined use produces the most pronounced outcomes.
Sermorelin vs Ipamorelin Mechanism
GHRH receptor cAMP/PKA pathway vs GHS-R1a calcium/PKC — two independent cascades studied in GH axis amplification protocols.
Best Peptides for Growth Hormone Research
Comprehensive guide to GHRPs and GHRH analogs studied for GH axis activation in laboratory settings.
Best Peptides for Fat Loss Research
Overview of GLP-1 agonists, MOTS-c, AOD-9604, and GHRPs studied in fat loss and metabolic research contexts.
Peptide Half-Life Research Guide
How half-life affects dosing intervals and study design across GHRPs, GLP-1s, and other peptide classes.
Research Use Only
All Ipamorelin research content is for educational and investigational purposes only. Not approved for human use.